Softwr

Healthcare · head to head

Rx30 vs Therapixel

Rx30 logo

Rx30

Healthcare

Long-established pharmacy management system for independents and small chains

From
On request
Rated
-
Full reviewWebsite
Therapixel logo

Therapixel

Healthcare

French mammography AI with FDA clearances for 2D and tomosynthesis breast screening

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Rx30 shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally; Therapixel european and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • They diverge on capability: Rx30 covers Prescription processing, Therapixel covers MammoScreen 2D.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Rx30 and Therapixel actually diverge.

Attributes where Rx30 and Therapixel differ
AttributeRx30Therapixel
PlatformsWindows, WebWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Rx30

  • Prescription processing
  • Claims adjudication
  • Inventory and purchasing
  • Point of sale
  • Delivery management
  • Clinical documentation

Only in Therapixel

  • MammoScreen 2D
  • MammoScreen DBT
  • One to ten suspicion score
  • Summary report
  • Workstation and PACS delivery
  • Reading workflow configurations

What people use each for

The jobs each tool is most often brought in to do.

Rx30

  • Independent pharmacies and small chains wanting a mature, widely-supported systemnot Therapixel
  • Operations relying on a broad set of wholesaler and PBM interfacesnot Therapixel
  • Pharmacies with significant front-end retail alongside dispensingnot Therapixel
  • Multi-store independents needing consistency across locationsnot Therapixel

Therapixel

  • A European breast screening programme running mandatory double reading that wants to evaluate AI as a concurrent or second reader within what national guidance permitsnot Rx30
  • An American breast centre that has moved to tomosynthesis and needs reading support on DBT specifically, which Therapixel holds a clearance fornot Rx30
  • A screening service wanting a graded suspicion score rather than a binary flag so readers can calibrate their own thresholdnot Rx30
  • A radiology group evaluating multiple mammography AI vendors head to head on their own historic case set before committingnot Rx30

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Rx30

  • Shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
  • The interface shows its age against newer entrants, and this is the most common objection in demonstrations
  • Pricing is not published, and total cost including hardware and interfaces needs to be requested explicitly
  • Windows-centric, with a cloud story less developed than newer competitors
  • US-only, tied to US insurance and regulatory requirements

Therapixel

  • European and American regulatory positions were established under different regimes, and under the EU Medical Device Regulation this class of diagnostic AI faces a higher classification and notified body scrutiny, so European buyers must verify the current MDR certificate and expiry rather than relying on a legacy CE reference.
  • MammoScreen does mammography only, so a hospital wanting AI across head CT, chest and breast needs several vendors and several PACS integrations, or an orchestration layer bought from someone else.
  • Therapixel is a small French company competing against Hologic and iCAD, which have incumbency inside the mammography reading workstation, so integration into an American breast centre is more work than it is for the workstation vendor own AI.
  • Detection performance is sensitive to the mammography unit vendor and acquisition protocol, so published results do not transfer between estates and each site needs local validation it must fund itself.
  • Whether AI can substitute for one of two human readers is a national workforce and liability question, not a product capability, so the labour saving that justifies the purchase in one country is not permitted in another.

Pricing, plan by plan

Rx30

On request
  • Rx30$undefined/month
    • Prescription processing
    • Claims adjudication
    • Inventory

Therapixel

On request
  • MammoScreen$undefined/year
    • Priced per examination or by annual screening volume
    • 2D and tomosynthesis licensed by the versions cleared for each
    • Cloud or on premises deployment quoted differently

Which should you pick?

Choose Rx30 if

  • You need prescription processing.
  • You work on Windows, Web.
  • You also want claims adjudication.
Rx30 review

Choose Therapixel if

  • You need mammoscreen 2d.
  • You also want mammoscreen dbt.
Therapixel review

Questions people ask

Is Rx30 or Therapixel better?
Neither clearly leads. Rx30 starts at On request and Therapixel at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Rx30 or Therapixel?
Rx30 starts at On request and Therapixel at On request.
Does Rx30 or Therapixel run on more platforms?
Rx30 runs on Windows, Web. Therapixel runs on Web.
What is Rx30 best used for?
Rx30 is most often used for independent pharmacies and small chains wanting a mature, widely-supported system, operations relying on a broad set of wholesaler and pbm interfaces, pharmacies with significant front-end retail alongside dispensing, multi-store independents needing consistency across locations. Of those, independent pharmacies and small chains wanting a mature, widely-supported system and operations relying on a broad set of wholesaler and pbm interfaces are not what Therapixel is typically brought in for.
What can Rx30 do that Therapixel cannot?
Rx30 covers Prescription processing, Claims adjudication, Inventory and purchasing, Point of sale. Therapixel covers MammoScreen 2D, MammoScreen DBT, One to ten suspicion score, Summary report.

Answered from the vendors’ own pages

Rx30: Is Rx30 the same company as PioneerRx?

Both are owned by RedSail Technologies. They are sold as separate products to overlapping markets, but roadmap decisions sit with one company, which is worth knowing before treating them as independent options.

Therapixel: Is MammoScreen FDA cleared?

Yes. It holds 510(k) clearance K192854 for two dimensional mammography from July 2020, a November 2021 clearance for digital breast tomosynthesis, and two further clearances in October 2024 for later versions.

Rx30: What does it cost?

Not published. Request the total including hardware, interfaces and training rather than the monthly software fee.

Therapixel: Is it CE marked?

Yes, but European buyers should ask specifically for the current certificate under the Medical Device Regulation and its expiry date, because this class of diagnostic AI moved to a higher classification under MDR.

Rx30: Why do pharmacies stay on it?

Installed base maturity. The interfaces to wholesalers, PBMs and hardware are long established, and those are the things that quietly stop a pharmacy working when they break.

Therapixel: What does the one to ten score mean?

It is a graded suspicion score per finding and per study, designed to be integrated alongside a radiologist BI-RADS assessment rather than treated as a positive or negative result.

Rx30: How does it compare to PioneerRx?

PioneerRx is more aggressively developed around clinical services. Rx30 has the larger legacy base and broader front-end retail heritage. Same owner, different emphasis.

Therapixel: Does it cover anything besides mammography?

No. It is a mammography product only, including tomosynthesis. Other body regions need a different vendor.

Rx30: Is it suitable for a small chain?

Yes, and that is one of its stronger cases. Multi-store consistency is better handled here than by the systems aimed purely at single independents.

Share

Related pages

More on Rx30

More on Therapixel

Keep looking

Other head to heads